LB Pharmaceuticals (LBRX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Savara (SVRA) over the past year, gaining 138.0% versus a gain of 43.9%. LB Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.01 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | SVRA |
|---|---|---|
| Share price | $37.22 | $4.92 |
| Market cap | $1.20B | $1.01B |
| 1-day change | +7.54% | +1.86% |
| YTD return | +67.21% | -18.41% |
| 1-year return | +137.98% | +43.86% |
| 5-year return | — | +281.40% |
| P/E ratio (TTM) | 372.20 | — |
| EPS (TTM) | $0.10 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $7.01 |
| 52-week low | $14.32 | $3.35 |
| Distance from 52-week high | -25.80% | -29.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +53.95% | +124.80% |
| Average volume | 344.34K | 1.83M |
| Shares outstanding | 32.26M | 205.46M |
| Employees | 49 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed SVRA by 94.1 percentage points over the past year.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
LBRX vs SVRA FAQ
Which is bigger, LB Pharmaceuticals or Savara?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.20B compared with $1.01B for Savara (SVRA).
Which stock has performed better over the past year, LBRX or SVRA?
LBRX returned +137.98% over the past 12 months, compared with +43.86% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are LB Pharmaceuticals and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.